Jyseleca 200 mg film-coated tablets
Sponsors
Alfasigma S.p.A., University Medical Center Utrecht, Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC), University Hospital Of Clermont-Ferrand, Medisch Spectrum Twente
Conditions
Behcet's diseaseDiagnosis of RA according to the ACR/EULAR 2010 criteria without a history of cardiovascular diseasesIdiopathic Inflammatory MyopathiesIgG4-related diseaseJuvenile idiopathic arthritisPolyarticular-course juvenile idiopathic arthritisRheumatoid arthritisRheumatoid arthritis according to 2010 criteria
Phase 1
Phase 2
Phase 3
A Phase 3 randomized, placebo-controlled, double-blind, parallel-group program to evaluate efficacy and safety of filgotinib in adult subjects with active axial spondyloarthritis
RecruitingCTIS2022-501354-10-01
Start: 2023-06-21Target: 487Updated: 2025-08-29
A Multicenter, Open-label, Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Subjects with Rheumatoid Arthritis
CompletedCTIS2024-513919-27-00
Start: 2017-09-14End: 2025-04-15Target: 254Updated: 2025-02-27
A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Ulcerative Colitis
Active, not recruitingCTIS2024-516199-14-00
Start: 2017-04-12Target: 26Updated: 2025-10-22
A multicenter study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of filgotinib, with single arm induction and maintenance, in pediatric subjects (8 to <18 years of age) with moderately to severely active ulcerative colitis
RecruitingCTIS2024-511458-32-00
Start: 2025-06-15Target: 68Updated: 2026-01-23
Open Label Extension (OLE), multiple dose study to evaluate pharmacokinetics, safety, tolerability and efficacy of filgotinib in children and adolescents from 8 years to less than 18 years of age with juvenile idiopathic arthritis (JIA).
Not yet recruitingCTIS2025-523239-21-00
Target: 18Updated: 2026-04-01
Multicenter, open-label study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of filgotinib in children and adolescents from 8 years to less than 18 years of age with polyarticular-course juvenile idiopathic arthritis
Not yet recruitingCTIS2024-511593-70-00
Target: 30Updated: 2026-04-08
FirST lines of biologics in pAtients with ulceRaTivE colitis: a Randomised controlled trial
Not yet recruitingCTIS2024-514964-24-00
Target: 240Updated: 2026-04-08
Phase 4
PeRsonalIzed MEdicine in Rheumatoid Arthritis (PRIMERA trial): a multicenter, open-label, randomized controlled trial comparing usual care with a tailor-made approach
Not yet recruitingCTIS2024-511530-12-01
Target: 300Updated: 2024-10-01
Filgotinib bridging in newly diagnosed rheumatoid arthritis patients (FAST RA trial); A pragmatic randomized controlled non-inferiority low intervention clinical trial
Not yet recruitingCTIS2024-517112-30-00
Target: 168Updated: 2025-01-16
The effect of Janus Kinase inhibitors on the heart in Rheumatoid Arthrtis
Not yet recruitingCTIS2025-520710-58-00
Target: 105Updated: 2025-07-09
REDO-JAK: Dose REDuction Of JAnus Kinase inhibitors in patients with inflammatory rheumatic diseases
RecruitingCTIS2025-520757-36-00
Start: 2025-09-15Target: 200Updated: 2026-01-13
STOP - Safety and efficacy of a STOPping strategy versus classical maintenance dose of JAK inhibitors in deep remission patients with ulcerative colitis: a randomized controlled trial
Not yet recruitingCTIS2026-525643-32-00
Target: 224Updated: 2026-06-17
Optimising Arthritis Strategies in Elderly patients (≥70 years) with rheumatoid arthritis in sustained low disease activity (the OASE study): A Prospective Target Trial Emulation Study Evaluating Tapering of Disease-Modifying Anti-Rheumatic Drugs vs. Usual Care Based on Patient Preference
Not yet recruitingCTIS2026-525221-21-01
Target: 180Updated: 2026-07-06